OncoCyte price target lowered to $1 from $1.50 at Piper Sandler

Piper Sandler analyst David Westenberg lowered the firm’s price target on OncoCyte to $1 from $1.50 and keeps an Overweight rating on the shares. The analyst updated his model to reflect the recent earnings report.